Search

Key updates

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

Study did not meet primary endpoint nor notable secondary endpoints – no benefit observed in either treatment arm versus shamAdditional analyses to be conducted and presented at a future medical congressSepofarsen continues to be generally well tolerated

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec.

LEIDEN, Netherlands and CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, The Netherlands, June 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, the Netherlands, Aug. 01, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing OligonucleotidesPreclinical proof of concept for the Company’